REGENXBIO (RGNX) awards RSUs, options to legal chief Patrick Christmas

Rhea-AI Filing Summary

REGENXBIO Inc. reported new equity awards to a senior executive. Chief Strategy & Legal Officer Patrick J. Christmas received 73,749 shares of common stock on January 6, 2026 at a reported price of $0.00, increasing his directly held common shares to 215,367.

The 73,749 shares represent a restricted stock unit award that vests 25% each on January 6 of 2027, 2028, 2029 and 2030, subject to continued service. On the same date, he was granted stock options for 39,650 shares with a $14.18 exercise price, expiring on January 6, 2036; 25% of these options vest after 12 months of continuous service, with the remainder vesting in equal monthly installments over the following 36 months. After this grant, he holds 39,650 options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christmas Patrick J.

(Last) (First) (Middle)

C/O REGENXBIO INC.

9804 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENXBIO Inc. [ RGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy & Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A		73,749(1)	A	$0.00	215,367	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$14.18	01/06/2026		A		39,650		(2)	01/06/2036	Common Stock	39,650	$0.00	39,650	D

Explanation of Responses:

1. Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 6, 2027, January 6, 2028, January 6, 2029 and January 6, 2030 while the recipient provides continuous service to the Issuer.

2. 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 6, 2027 while the optionee provides continuous service to the Issuer.

Remarks:

	/s/ Patrick J. Christmas	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did REGENXBIO (RGNX) disclose in this Form 4?

The filing shows Chief Strategy & Legal Officer Patrick J. Christmas received 73,749 shares of common stock and 39,650 stock options on January 6, 2026, as equity compensation awards.

Who is the reporting person in the REGENXBIO (RGNX) Form 4?

The reporting person is Patrick J. Christmas, who serves as Chief Strategy & Legal Officer of REGENXBIO Inc.

How do the 73,749 REGENXBIO (RGNX) RSUs for Patrick Christmas vest?

The 73,749 restricted stock units vest in four equal installments: 25% on each of January 6, 2027, 2028, 2029, and 2030, provided he continues to provide service to the company.

What are the key terms of the 39,650 REGENXBIO (RGNX) stock options granted?

The stock options cover 39,650 shares of common stock at a $14.18 exercise price, expiring on January 6, 2036. Twenty-five percent vest after 12 months of continuous service, and the remaining 75% vest in equal monthly installments over the following 36 months.

How many REGENXBIO (RGNX) shares does Patrick Christmas own after these transactions?

After the reported grant, Patrick J. Christmas beneficially owns 215,367 shares of common stock directly, along with 39,650 stock options.

Were the REGENXBIO (RGNX) equity awards to Patrick Christmas direct or indirect holdings?

Both the 73,749 shares of common stock and the 39,650 stock options are reported as direct (D) ownership by Patrick J. Christmas.